ReviewAllergy, asthma & immunology research2022
Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update.
Review in Allergy, asthma & immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 64 citations in OpenAlex.
- A multicenter randomized study: safety of an optimized accelerated house dust mite immunotherapy for patients with allergic rhinitis in China (PERFECT study).Frontiers in immunology · 2026Trial
- Nasal saline irrigation with azelastine-fluticasone nasal spray in moderate-to-severe persistent allergic rhinitis: a randomized controlled trial.Frontiers in allergy · 2025Trial
- Recent advances in allergen immunotherapy.Chinese medical journal · 2026Review
- Unraveling the increasing burden of allergies: Spatiotemporal dynamics of pollen allergy risk in China.Eco-Environment & Health · 2026Article
- Forecasting seasonal allergic rhinitis through integrated analysis of social media and online drug sales data.The World Allergy Organization journal · 2026Article
- Study ofInternational journal of molecular sciences · 2026Article
- Article
- Knowledge, attitudes, and practice towards allergen-specific immunotherapy in parents with children having allergic rhinitis: a cross-sectional study in Wuxi.BMC pediatrics · 2026Article
- Multi-targeted protection of Yuping Tongqiao against allergic rhinitis: suppression of inflammatory response via TSLP signaling and reinforcement of epithelial barrier integrity via AhR signaling.Frontiers in allergy · 2026Article
- Comorbidity of Allergic Asthma and Rhinitis and High Allergen-Specific IgE are Risk Factors for Systemic Reactions to House Dust Mite Immunotherapy in Children.Journal of asthma and allergy · 2026Article
- Local immune and inflammatory endotypes of the nasal mucosa in allergic and non-allergic chronic rhinitis.Frontiers in immunology · 2026Article
- Serum metabolomic profiling identifies taurolithocholic acid as a predictor of HDM-SCIT response in allergic rhinitis: clinical discovery and experimental validation.Frontiers in immunology · 2026Article
- RGS1 induces nasal epithelial barrier dysfunction in allergic rhinitis by modulating NF-κB/AQP5 axis.Cytotechnology · 2025Article
- Landscape of Aeroallergen Sensitization in Asia.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Allergic rhinitis in college students at Dongguan: a cross-sectional survey on disease burden, knowledge, and self-management.Frontiers in allergy · 2025Article
- A study of specific immunoglobulin G4 expression in allergic rhinitis and its value in assessing efficacy and in predicting prognosis of sublingual immunotherapy.The Kaohsiung journal of medical sciences · 2025Article
- Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers.The World Allergy Organization journal · 2025Article
- Analysis of gender- and age-stratified asthma burden: forecasting prevalence trends in 2030.Frontiers in medicine · 2025Article
- Reliability and validity of a newly developed self-administrated online questionnaire assessing the quality of life for allergic rhinitis in China: The QoLAR.Journal of education and health promotion · 2025Article
- Elevated SerpinB2 regulates MUC5AC expression via STAT6 signaling in nasal epithelial cells in allergic rhinitis.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last few decades, there has been a progressive increase in the prevalence of allergic rhinitis (AR) in China, where it now affects approximately 250 million people. AR prevention and treatment include allergen avoidance, pharmacotherapy, allergen immunotherapy (AIT), and patient education, among which AIT is the only curative intervention. AIT targets the disease etiology and may potentially modify the immune system as well as induce allergen-specific immune tolerance in patients with AR. In 2017, a team of experts from the Chinese Society of Allergy (CSA) and the Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) produced the first English version of Chinese AIT guidelines for AR. Since then, there has been considerable progress in basic research of and clinical practice for AIT, especially regarding the role of follicular regulatory T (TFR) cells in the pathogenesis of AR and the use of allergen-specific immunoglobulin E (sIgE) in nasal secretions for the diagnosis of AR. Additionally, potential biomarkers, including TFR cells, sIgG4, and sIgE, have been used to monitor the incidence and progression of AR. Moreover, there has been a novel understanding of AIT during the coronavirus disease 2019 pandemic. Hence, there was an urgent need to update the AIT guideline for AR by a team of experts from CSA and C2AR2G. This document aims to serve as professional reference material on AIT for AR treatment in China, thus improving the development of AIT across the world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.